Arcutis Says Health Canada Accepts For Review Roflumilast Cream NDS For Plaque Psoriasis
(RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT) announced Monday that Health Canada has accepted for review the New Drug Submission (NDS) for roflumilast cream 0.3% for the treatment of plaque psoriasis in adults and adolescents. The target action date is April 30, 2023.
Roflumilast cream (ARQ-151) is a once-daily topical formulation of roflumilast, a highly potent and selective inhibitor of phosphodiesterase type 4 (PDE4), an enzyme that drives overactive immune responses. PDE4 is an established target in dermatology.
Arcutis' NDS submission is supported by positive data from Arcutis' pivotal Phase 3 program and two long-term open label studies. DERMIS-1 and DERMIS-2 were identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multi-national, multi-center studies to evaluate the safety and efficacy of roflumilast cream 0.3%.
A new drug application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adolescents and adults is also under review by the U.S. Food & Drug Administration (FDA). The FDA has set a target action date of July 29, 2022.
For More Such Health News, visit rttnews.com
Arcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFO
FTSE Up Marginally; Spirax Group Shares Jump On Strong Earnings
Euro Slides On Downbeat German Economic Sentiment Data
CAC 40 Up Marginally In Cautious Trade
Sensex, Nifty End Lower With Banks Under Pressure
Pound Rises On Upbeat U.K. Employment Data
DAX Retreats After Positive Start, Down 0.3%
